Free Trial

ProKidney Stock Earnings Estimates Reduced by HC Wainwright

ProKidney logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright cut its FY2030 EPS estimate for ProKidney to $0.05 from $0.08. The company’s latest quarterly loss was $0.17 per share, one cent worse than analysts expected, while revenue of $0.17 million topped estimates.
  • ProKidney shares opened at $1.04, near their one-year low of $0.87 and below their 50- and 200-day moving averages. Analysts’ average rating is “Moderate Buy,” with an average price target of $10.
  • Company insiders sold 757,164 shares worth about $1.07 million over the past 90 days. ProKidney is a clinical-stage biotech developing the investigational kidney cell therapy REACT.
  • MarketBeat previews top five stocks to own in December.

ProKidney Corp. (NASDAQ:PROK - Free Report) - Investment analysts at HC Wainwright lowered their FY2030 earnings estimates for ProKidney in a research note issued on Friday, November 13th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of $0.05 for the year, down from their prior estimate of $0.08. The consensus estimate for ProKidney's current full-year earnings is ($0.51) per share.

ProKidney (NASDAQ:PROK - Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.01). The firm had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.12 million.

Several other research firms also recently weighed in on PROK. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of ProKidney in a research note on Tuesday, October 6th. Citigroup decreased their target price on ProKidney to $8.00 and set a "buy" rating on the stock in a research report on Wednesday, October 28th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, ProKidney has an average rating of "Moderate Buy" and an average price target of $10.00.

View Our Latest Analysis on ProKidney

ProKidney Price Performance

PROK opened at $1.04 on Monday. The stock has a market cap of $315.92 million, a P/E ratio of -1.74 and a beta of 1.90. The stock's 50 day simple moving average is $1.53 and its 200 day simple moving average is $1.77. ProKidney has a 1-year low of $0.87 and a 1-year high of $2.65.

Insiders Place Their Bets

In other ProKidney news, Director Brian Pereira sold 229,338 shares of the firm's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $1.37, for a total transaction of $314,193.06. Following the completion of the transaction, the director directly owned 445,897 shares in the company, valued at approximately $610,878.89. This trade represents a 33.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last ninety days, insiders have sold 757,164 shares of company stock worth $1,067,315. Company insiders own 39.83% of the company's stock.

Institutional Trading of ProKidney

Several large investors have recently modified their holdings of PROK. Russell Investments Group Ltd. increased its stake in shares of ProKidney by 163.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 15,958 shares of the company's stock worth $26,000 after purchasing an additional 9,908 shares in the last quarter. SummitTX Capital L.P. acquired a new position in shares of ProKidney during the 1st quarter worth approximately $26,000. StoneX Group Inc. acquired a new position in shares of ProKidney during the 3rd quarter worth approximately $30,000. Voya Investment Management LLC purchased a new stake in ProKidney in the 3rd quarter valued at approximately $37,000. Finally, FNY Investment Advisers LLC lifted its stake in ProKidney by 2,000.0% in the 2nd quarter. FNY Investment Advisers LLC now owns 21,000 shares of the company's stock valued at $42,000 after buying an additional 20,000 shares in the last quarter. 51.59% of the stock is currently owned by institutional investors and hedge funds.

About ProKidney

(Get Free Report)

ProKidney is a clinical-stage biotechnology company developing cell therapies for people with chronic kidney disease. The company's work focuses on treatments intended to help preserve kidney function, particularly in patients with diabetic kidney disease. Its lead investigational product, REACT (REnal Autologous Cell Therapy), is made from cells collected from a patient's own kidney tissue. The cells are processed and delivered back to the patient's kidney. REACT is being evaluated in clinical trials and is not an approved treatment.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in ProKidney Right Now?

Before you consider ProKidney, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProKidney wasn't on the list.

While ProKidney currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines